Cartesian Therapeutics (RNAC) Equity Average (2016 - 2025)
Historic Equity Average for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to -$19.2 million.
- Cartesian Therapeutics' Equity Average rose 6189.8% to -$19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.2 million, marking a year-over-year increase of 6189.8%. This contributed to the annual value of -$223.5 million for FY2024, which is 2905.39% down from last year.
- Latest data reveals that Cartesian Therapeutics reported Equity Average of -$19.2 million as of Q3 2025, which was up 6189.8% from -$12.2 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Equity Average peaked at $89.4 million during Q4 2022, and registered a low of -$278.5 million during Q1 2024.
- Moreover, its 5-year median value for Equity Average was -$11.5 million (2021), whereas its average is -$11.1 million.
- Its Equity Average has fluctuated over the past 5 years, first tumbled by 1016693.99% in 2021, then surged by 461596.31% in 2022.
- Quarter analysis of 5 years shows Cartesian Therapeutics' Equity Average stood at $1.9 million in 2021, then skyrocketed by 4615.96% to $89.4 million in 2022, then crashed by 312.52% to -$189.9 million in 2023, then skyrocketed by 98.41% to -$3.0 million in 2024, then tumbled by 534.23% to -$19.2 million in 2025.
- Its Equity Average stands at -$19.2 million for Q3 2025, versus -$12.2 million for Q2 2025 and -$14.3 million for Q1 2025.